Precipio

PRPO

Market cap $42M

PRPO's first-quarter 2026 sales are driven by pathology momentum, but CMS reimbursement cuts and higher spending squeeze margins and widen losses.

Precipio, Inc. (PRPO) Q1 2026 Earnings Call Transcript

Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth

NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company  Precipio, Inc.   (NASDAQ: PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted.

AI demand and pipeline growth headline top Zacks stock reports on NVIDIA, Mastercard and AbbVie.

NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc.   (NASDAQ: PRPO) , will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET.

Precipio, Inc. (PRPO) Q4 2025 Earnings Call Prepared Remarks Transcript

NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET.

In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M

Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding Less than $80,000 of long-term debt, and 10,000 vendor warrants remain outstanding